ZEJULA

Growth

niraparib

NDAORALTABLET
Approved
Apr 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

enzymes, including PARP-1 and PARP-2, that play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death. Increased…

Clinical Trials (5)

NCT06412120Phase 4Recruiting

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Started Jun 2026
70 enrolled
Ovarian Cancer
NCT06392841Phase 2Withdrawn

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Started Oct 2025
0
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene Mutation+7 more
NCT06747845Phase 2Recruiting

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Started May 2025
68 enrolled
Pancreatic Adenocarcinoma Metastatic
NCT06527690Phase 2Withdrawn

Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer

Started Apr 2025
0
Prostate CancerCastrate Resistant Prostate CancerHomologous Recombination Deficiency
NCT06887933Phase 4Not Yet Recruiting

A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer

Started Apr 2025
67 enrolled
Ovarian Neoplasms

Loss of Exclusivity

LOE Date
Jan 25, 2039
157 months away
Patent Expiry
Jan 25, 2039

Patent Records (5)

Patent #ExpiryTypeUse Code
8143241
Aug 12, 2027
U-2655
8071579
Aug 12, 2027
U-2655
8436185
Apr 24, 2029
Substance
8071623
Mar 27, 2031
SubstanceProduct
8859562
Aug 4, 2031
U-2655